A Phase 3 interventional study of Deucravacitinib and Ustekinumab in Plaque Psoriasis, sponsored by Bristol-Myers Squibb. Recruiting at 411 sites in 25 countries. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2026-10-28.
Sponsored by Bristol-Myers Squibb · Phase 3, Interventional, and Treatment
A study to evaluate the long-term safety of Deucravacitinib versus Ustekinumab in participants with psoriasis
2,028 studies on the registry are indexed under Psoriasis; 275 are open to participants now.
This study's planned enrollment of 3,040 is above the median of 75 across 1,565 interventional studies indexed under Psoriasis.
Browse Psoriasis studies →Bristol-Myers Squibb is the lead sponsor of 1,561 studies on the registry; 117 are open to participants now.
Of its 436 completed or terminated interventional studies of FDA-regulated products, 228 (52%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Participants with moderate-to-severe plaque psoriasis:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Deucravacitinib
Drug: Ustekinumab
Specified dose on specified days
Also known as: SOTYKTU
Specified dose on specified days
Composite cardiovascular adjudicated 3-point major adverse cardiovascular event (MACE) plus coronary revascularization
MACE defined as non-fatal myocardial infarction \[MI\], nonfatal stroke, and cardiovascular death
Time frame: Up to 5 years
Number of participants with non-fatal MI
Time frame: Up to 5 years
Number of participants with non-fatal stroke
Time frame: Up to 5 years
Death due to cardiovascular events
Time frame: Up to 5 years
Number of participants with coronary revascularization
Time frame: Up to 5 years
Number of participants with 3-point MACE (non-fatal MI, non-fatal stroke, and cardiovascular death)
Time frame: Up to 5 years
Number of participants with pulmonary embolism (PE)
Time frame: Up to 5 years
Number of participants with deep vein thrombosis (DVT)
Time frame: Up to 5 years
Number of participants with composite venous thromboembolism (VTE)
PE, DVT and retinal vein occlusion
Time frame: Up to 5 years
Number of participants with arterial thromboembolic events (including retinal artery occlusion)
Time frame: Up to 5 years
Number of participants with heart failure (HF) requiring hospitalization or urgent visit
Time frame: Up to 5 years
Number of participants with Malignancy excluding non-melanoma skin cancer (NMSC)
Time frame: Up to 5 years
Number of participants with NMSC
Time frame: Up to 5 years
Number of participants with opportunistic infections
Opportunistic infections include tuberculosis and complicated herpes zoster (eg, disseminated herpes zoster, affecting more than 2 dermatomes, ophthalmic or meningoencephalopathic involvement, and other atypical presentations)
Time frame: Up to 5 years
Number of participants with Serious AEs (SAEs)
Time frame: Up to 60 days after last dose
All-cause mortality
Time frame: Up to 60 days after last dose
AEs leading to permanent treatment discontinuation
Time frame: Up to 60 days after last dose
Change from baseline in liver function test
Time frame: Up to 60 days after last dose
Change from baseline in fasting lipid panel
Time frame: Up to 60 days after last dose
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Showing the first 100 of 411 sites across 25 countries. Choose a country and city above to see the rest.
Plan to share: Yes — BMS will provide access to individual anonymized participant data upon request from qualified researchers, and subject to certain criteria. Additional information regarding Bristol Myer Squibb's data sharing policy and process can be found at https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: See Plan Description
Access criteria: See Plan Description
Data sharing details ↗ · www.bms.com
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Deucravacitinib